Literature DB >> 25550870

Intravascular large B-cell lymphoma manifesting as cholecystitis: report of an Asian variant showing gain of chromosome 18 with concurrent deletion of chromosome 6q.

Shogo Tajima1, Michihiko Waki2, Hiroyuki Yamazaki3, Yasuyuki Nagata2, Hana Fukano2, Md Amir Hossen2, Shoji Hoshi1, Takahiro Takeuchi4.   

Abstract

Intravascular large B-cell lymphoma (IVLBCL), which involves the lumen of small vessels, is a rare variant of extranodal diffuse large B-cell lymphomas. Herein, we present a case of IVLBCL manifesting as cholecystitis in a 77-year-old Japanese man. He presented with fever, fatigue, and weight loss. Physical examination revealed tenderness of the right upper quadrant. The white blood cell count and C-reactive protein levels were elevated. Computed tomography revealed gallbladder thickening and pericholecystic fluid collection; these observations were consistent with the diagnosis of cholecystitis. Serum soluble interleukin-2 receptor levels were highly elevated, and gallium scintigraphy revealed an abnormal accumulation in the spleen, implying lymphoma. Consequently, G-banding analysis of the patient's bone marrow aspirates revealed the presence of different abnormal clones, including those with gain of chromosome 18 and deletion of chromosome 6q. As cholecystectomy was necessary, a concurrent splenectomy was performed to diagnose the disease definitively. Histopathologically, atypical large lymphoid cells were observed to be localized in the vasculature in both the spleen and gallbladder; the atypical cells expressed high levels of CD20, CD5, and CD10, immunohistochemically. These findings were consistent with IVLBCL. The patient underwent post-operative treatment with rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone. However, a pancreatic fistula developed during chemotherapy, causing left pleural effusion and peritoneal effusion; the patient developed sepsis from multidrug-resistant microorganisms, and subsequently died of multi-organ failure 6 months after the diagnosis. No obvious recurrence of the tumor was found during autopsy. We discuss the characteristic karyotype and immunohistochemical status observed in this case.

Entities:  

Keywords:  Asian variant; Intravascular large B-cell lymphoma; autopsy; deletion of chromosome 6q; gain of chromosome 18; gallbladder

Mesh:

Year:  2014        PMID: 25550870      PMCID: PMC4270622     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  Intravascular large B-cell lymphoma presenting as cholecystitis and pancytopenia: case report with literature review.

Authors:  Xiuzhen Duan; Angelo Lapus; Robert E Brown; Lei Chen
Journal:  Ann Clin Lab Sci       Date:  2011       Impact factor: 1.256

2.  Detection of t(14;18) translocation in a case of intravascular large B-cell lymphoma: a germinal centre cell origin in a subset of these lymphomas?

Authors:  B Vieites; M Fraga; E Lopez-Presas; E Pintos; A Garcia-Rivero; J Forteza
Journal:  Histopathology       Date:  2005-04       Impact factor: 5.087

Review 3.  Intravascular lymphoma: a neoplasm of 'homeless' lymphocytes?

Authors:  Maurilio Ponzoni; Andrés J M Ferreri
Journal:  Hematol Oncol       Date:  2006-09       Impact factor: 5.271

4.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.

Authors:  Maurilio Ponzoni; Andrés J M Ferreri; Elías Campo; Fabio Facchetti; Luca Mazzucchelli; Tadashi Yoshino; Takuhei Murase; Stefano A Pileri; Claudio Doglioni; Emanuele Zucca; Franco Cavalli; Shigeo Nakamura
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

Review 5.  Presentation and management of intravascular large B-cell lymphoma.

Authors:  Kazuyuki Shimada; Tomohiro Kinoshita; Tomoki Naoe; Shigeo Nakamura
Journal:  Lancet Oncol       Date:  2009-09       Impact factor: 41.316

6.  Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.

Authors:  Takuhei Murase; Motoko Yamaguchi; Ritsuro Suzuki; Masataka Okamoto; Yumiko Sato; Jun-ichi Tamaru; Masaru Kojima; Ikuo Miura; Naoyoshi Mori; Tadashi Yoshino; Shigeo Nakamura
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

7.  Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma.

Authors:  Kosei Matsue; Noboru Asada; Jun Odawara; Takayoshi Aoki; Shun-ichi Kimura; Kan-ichi Iwama; Hideaki Fujiwara; Masayuki Yamakura; Masami Takeuchi
Journal:  Ann Hematol       Date:  2010-10-19       Impact factor: 3.673

Review 8.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

9.  An Asian variant of intravascular lymphoma: unique clinical and pathological manifestation in the gallbladder.

Authors:  N Kuroda; M Mizobuchi; Y Shimamura; Y Taniguchi; M Daibata; I Miyoshi; T Ichimura; H Beppu; M Ohara; T Hirouchi; K Mizuno; G H Lee
Journal:  APMIS       Date:  2007-04       Impact factor: 3.205

10.  Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs.

Authors:  T Wagner; D Brechemier; E Dugert; S Le Guellec; A Julian; A Hitzel; O Beyne-Rauzy
Journal:  Cancer Imaging       Date:  2012-01-23       Impact factor: 3.909

View more
  2 in total

1.  Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature.

Authors:  Yingying Han; Qingjiao Li; Dan Wang; Lushan Peng; Tao Huang; Chunlin Ou; Keda Yang; Junpu Wang
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

2.  A case of intravascular large B cell lymphoma presenting as nodular goiter.

Authors:  Bo Luo; Jia-Mei Chen; Jie Liu; Wen-He Li; Yu-Xiang Shi; Pan Zeng; Yong-Hui Xie; Hong-Feng Zhang
Journal:  Diagn Pathol       Date:  2017-08-25       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.